Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Arschang Valipour, Michael Tamm, Jana Kociánová, Valentina Bayer, Maria Sanzharovskaya, Alexey Medvedchikov, Monika Haaksma-Herczegh, János Mucsi, Zvi Fridlender, Claudia Toma, Andrey Belevskiy, Bohumil Matula & Jurij Šorli. (2019) Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 2343-2354.
Read now
Read now
Karl-Otto Steinmetz, Birgit Abenhardt, Stefan Pabst, Michaela Hänsel, Anke Kondla, Valentina Bayer & Roland Buhl. (2019) Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 1441-1453.
Read now
Read now
Rüdiger Sauer, Michaela Hänsel, Roland Buhl, Roman A Rubin, Marcel Frey & Thomas Glaab. (2016) Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 891-898.
Read now
Read now
Soichiro Hanada, Shota Wada, Takeshi Ohno, Hirochiyo Sawaguchi, Masato Muraki & Yuji Tohda. (2015) Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 69-77.
Read now
Read now
Articles from other publishers (8)
Epaminondas Kosmas, Iraklis Titopoulos, Georgios Patentalakis & Nikos Nikas. (2021) An Observational Study Assessing Changes in Health and Functional Status in Patients with Chronic Obstructive Pulmonary Disease (COPD) During Therapy with Spiolto® Respimat® in Everyday Clinical Practice: The Greek ELLACTO Study. Pulmonary Therapy 7:2, pages 429-443.
Crossref
Crossref
Miguel Román-Rodríguez & Janwillem W. H. Kocks. (2021) Targeting exertional breathlessness to improve physical activity: the role of primary care. npj Primary Care Respiratory Medicine 31:1.
Crossref
Crossref
François Maltais, Alberto de la Hoz, Richard Casaburi & Denis O’Donnell. (2020) Effects of Tiotropium/Olodaterol on Activity-Related Breathlessness, Exercise Endurance and Physical Activity in Patients with COPD: Narrative Review with Meta-/Pooled Analyses. Advances in Therapy 38:2, pages 835-853.
Crossref
Crossref
Antonio Anzueto & Marc Miravitlles. (2020) Tiotropium in chronic obstructive pulmonary disease – a review of clinical development. Respiratory Research 21:1.
Crossref
Crossref
Mauro Carone, Alfio Pennisi, Mariella D’Amato, Alfeo Fiore Donati, Alberto Ricci, Carla Scognamillo, Li Chun, Maria Aliani, Valeria Ronsivalle & Girolamo Pelaia. (2020) Physical Functioning in Patients with Chronic Obstructive Pulmonary Disease Treated with Tiotropium/Olodaterol Respimat in Routine Clinical Practice in Italy. Pulmonary Therapy 6:2, pages 261-274.
Crossref
Crossref
Katherine A. Lyseng-Williamson & Gillian M. Keating. (2015) Tiotropium Respimat® Soft Mist™ inhaler: a guide to its use in chronic obstructive pulmonary disease (COPD) in the EU. Drugs & Therapy Perspectives 31:2, pages 39-44.
Crossref
Crossref
Gillian M. Keating. (2014) Tiotropium Respimat® Soft Mist™ Inhaler: A Review of Its Use in Chronic Obstructive Pulmonary Disease. Drugs 74:15, pages 1801-1816.
Crossref
Crossref
E.A. Kortianou, Z. Louvaris, M. Vasilopoulou, I. Nasis, G. Kaltsakas, N.G. Koulouris & I. Vogiatzis. (2013) Activity monitoring reflects cardiovascular and metabolic variations in COPD patients across GOLD stages II to IV. Respiratory Physiology & Neurobiology 189:3, pages 513-520.
Crossref
Crossref